Crohn’s Disease (CD) Therapeutics - Pipeline Assessment and Market Forecasts to 2018

Report Summary

GlobalData, the industry analysis specialist, has released its new report, Crohn’s Disease (CD) Therapeutics - Pipeline Assessment and Market Forecasts to 2018. The report is an essential source of information and analysis on the global Crohn’s Disease Therapeutics market. The report identifies the key trends shaping and driving the global Crohn’s Disease Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Crohn’s Disease Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

GlobalData has estimated that the global Crohn’s disease (CD) therapeutics market was worth $3.6 billion in 2010 which grew at a compound annual growth rate (CAGR) of 25.2%, from $1.2 billion in 2005. This high growth rate during the period 2005-2010 was primarily attributed to the launch of the biologics such as Humira (adalimumab), Cimzia (certolizumab pegol) and Tysabri (natalizumab) and the increased uptake of the biologics Remicade (infliximab) and Entocort EC (budesonide). The CD therapeutics market is forecast to show moderate growth at a CAGR of 2.6% for the next eight years, to reach $4.4 billion by 2018. This reduced growth will come as a result of the patent expiries of Remicade and Entocort EC and the subsequent launch of biosimilars in the forecast period. The CD therapeutics pipeline is strong, with first-in-class molecules in the late stage of development, which when launched are expected to off-set the generic incursion and drive the market.

Scope

The report provides information on the key drivers and challenges for the CD therapeutics market. Its scope includes -

• Annualized information for the CD therapeutics market in the seven key markets (the US, France, Germany, Italy, Spain, the UK and Japan) with revenue data from 2005–2010 and forecasts to 2018.
• Pipeline analysis data which provides information on different phases, mechanisms of action being developed and emerging trends. Pipeline candidates fall under major therapeutic classes such as interleukin inhibitors and enzyme inhibitors, stem cell therapy, integrin antagonists, tumor necrosis inhibitors and immunomodulators.
• Analysis of current and future competition in the global CD therapeutics market. Key market companies covered are: GlaxoSmithKline plc, Johnson & Johnson, Osiris Therapeutics, Inc., and Takeda Pharmaceutical Company Limited..
• Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
• Key topics covered include strategic competitor assessment, market characterization, unmet needs and implications for the CD therapeutics market.
• Analysis of key recent licensing and partnership agreements in the CD therapeutics market.

Reasons to buy

The report will enhance your decision making capability. It will allow you to -

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and through identification of companies with the strongest pipelines.
• Develop business strategies through understanding of the trends which shape and drive the global CD therapeutics market.
• Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to impact the global CD therapeutics market in the future.
• Formulate effective sales and marketing strategies through understanding of the competitive landscape and analysis of the performance of various competitors.
• Identify emerging companies with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Organize your sales and marketing efforts by identifying market categories and segments that present the best opportunities for consolidations, investments and strategic partnerships.
• What’s the next big thing in the global CD therapeutics market landscape? Identify, understand and capitalize.

Table of Contents

1 Table of Contents 3
1.1 List of Tables 5
1.2 List of Figures 6

2 Crohn’s Disease(CD) Therapeutics - Introduction 7
2.1 Overview 7
2.2 Types of CD 7
2.3 Perianal Complications 7
2.3.1 Classification of Perianal Complications 7
2.4 CD Diagnosis and Classification based on Severity and Location 8
2.5 Epidemiology 9
2.6 Etiology 9
2.7 Signs and Symptoms 10
2.8 Extraintestinal Manifestations of CD 10
2.9 Diagnosis of CD 11
2.10 Pathophysiology 12
2.11 Treatment and Management Pattern 13
2.11.1 Medical or Pharmacological Management of CD 13
2.11.2 Surgical Management of CD 15
2.12 GlobalData Report Guidance 16

3 Crohn’s Disease (CD) Therapeutics - Market Characterization 17
3.1 CD Therapeutics Market Size (2005 - 2010) - Global 17
3.2 CD Therapeutics Market Forecast (2010 - 2018) - Global 19
3.3 CD Therapeutics Market Size (2005 - 2010) - The US 21
3.4 CD Therapeutics Market Forecast (2010 - 2018) - The US 22
3.5 CD Therapeutics Market Size (2005 - 2010) - France 23
3.6 CD Therapeutics Market Forecast (2010 - 2018) - France 24
3.7 CD Therapeutics Market Size (2005 - 2010) - Germany 25
3.8 CD Therapeutics Market Forecast (2010 - 2018) - Germany 26
3.9 CD Therapeutics Market Size (2005 - 2010) - Italy 27
3.10 CD Therapeutics Market Forecast (2010 - 2018) - Italy 28
3.11 CD Therapeutics Market Size (2005 - 2010) - Spain 29
3.12 CD Therapeutics Market Forecast (2010 - 2018) - Spain 30
3.13 CD Therapeutics Market Size (2005 - 2010) - The UK 31
3.14 CD Therapeutics Market Forecast (2010 - 2018) - The UK 32
3.15 CD Therapeutics Market Size (2005 - 2010) - Japan 33
3.16 CD Therapeutics Market Forecast (2010 - 2018) - Japan 34
3.17 Drivers and Barriers for the CD Therapeutics Market 35
3.17.1 Drivers for the CD Therapeutics Market 35
3.17.2 Barriers for the CD Therapeutics Market 35
3.18 Key Events Impacting the Future Market 36
3.19 Opportunity and Unmet Need 37
3.20 Key Takeaway 38

4 Crohn`s Disease (CD) Therapeutics - Competitive Assessment 39
4.1 Overview 39
4.2 Strategic Competitor Assessment 39
4.3 Product Profile for the Major Marketed Products in the CD Therapeutics Market 40
4.3.1 Entocort EC (budesonide) 40
4.3.2 Humira (adalimumab) 41
4.3.3 Tysabri (natalizumab) 42
4.3.4 Remicade (infliximab) 43
4.3.5 Cimzia (cetrolizumab pegol) 44
4.4 Key Takeaway 45

5 Crohn`s Disease (CD) Therapeutics - Pipeline Assessment 46
5.1 Overview 46
5.2 Strategic Pipeline Assessment 46
5.3 CD Therapeutics Pipeline Analysis - Pipeline by Phases of Development 47
5.3.1 CD Therapeutics - Phase III Pipeline 47
5.3.2 CD Therapeutics - Phase II/III Pipeline 47
5.3.3 CD Therapeutics - Phase II Pipeline 48
5.3.4 CD Therapeutics - Phase I/II Pipeline 48
5.3.5 CD Therapeutics - Phase I Pipeline 49
5.3.6 CD Therapeutics - Preclinical Pipeline 49
5.3.7 CD Therapeutics - Discovery Pipeline 49
5.4 CD Therapeutics- Clinical Pipeline by Mechanism of Action 50
5.5 CD Therapeutics-Technology Trends Analytical Framework 51
5.6 CD Therapeutics - Promising Drugs with Novel mechanisms of action under Clinical Development 52
5.7 Molecule Profile for Late-stage Drugs under Clinical Development 53
5.7.1 Traficet-EN (CCX282) 53
5.7.2 Vedolizumab (MLN0002) 53
5.7.3 Prochymal 54
5.7.4 Stelara 54
5.8 Key Takeaway 55

6 Crohn’s Disease (CD) Therapeutics - Clinical Trials Mapping 56
6.1 Clinical Trials by Country (US, EU5 and Japan) 56
6.2 Clinical Trials by Phase 57
6.3 Clinical Trials by Trial Status 58
6.4 Overall Sponsors 59
6.5 Prominent Sponsor 60
6.6 Top Companies Participating in Therapeutics Clinical Trials, 2011 61

7 Crohn’s Disease (CD) Therapeutics - Strategic Assessment 62
7.1 CD Therapeutics Market - Implications for Future Market Competition 62

8 Crohn’s Disease (CD) Therapeutics - Future Players 63
8.1 Introduction 63
8.2 Company Profile 63
8.2.1 GlaxoSmithKline 63
8.2.2 Johnson & Johnson 65
8.2.3 Osiris Therapeutics, Inc. 66
8.2.4 Takeda Pharmaceutical Company Limited 68

9 Crohn`s Disease (CD) Therapeutics - Licensing and Partnership Deals 70

10 Crohn`s Disease (CD) Therapeutics - Appendix 73
10.1 Definitions 73
10.2 Acronyms 73
10.3 Research Methodology 74
10.3.1 Coverage 74
10.3.2 Secondary Research 75
10.3.3 Forecasting 75
10.3.4 Primary Research 77
10.3.5 Expert Panel Validation 78
10.4 Contact Us 78
10.5 Disclaimer 78
10.6 Bibliography 79

List of Tables

Table 1: Definitions of CD Activity 8
Table 2: Estimated Prevalence of CD in the Seven Major Key Markets 9
Table 3: Extraintestinal Manifestations of CD 10
Table 4: CD Therapeutics Market, Global, Revenue ($bn), 2005 - 2010 17
Table 5: CD Therapeutics Market, Global, Forecast ($bn), 2010 - 2018 19
Table 6: CD Therapeutics Market, The US, Revenue ($bn), 2005 - 2010 21
Table 7: CD Therapeutics Market, The US, Forecast ($bn), 2010 - 2018 22
Table 8: CD Therapeutics Market, France, Revenue ($m), 2005 - 2010 23
Table 9: CD Therapeutics Market, France, Forecast ($m), 2010 - 2018 24
Table 10: CD Therapeutics Market, Germany, Revenue ($m), 2005 - 2010 25
Table 11: CD Therapeutics Market, Germany, Forecast ($m), 2010 - 2018 26
Table 12: CD Therapeutics Market, Italy, Revenue ($m), 2005 - 2010 27
Table 13: CD Therapeutics Market, Italy, Forecast ($m), 2010 - 2018 28
Table 14: CD Therapeutics Market, Spain, Revenue ($m), 2005 - 2010 29
Table 15: CD Therapeutics Market, Spain, Forecast ($m), 2010 - 2018 30
Table 16: CD Therapeutics Market, The UK, Revenue ($m), 2005 - 2010 31
Table 17: CD Therapeutics Market, The UK, Forecast ($m), 2010 - 2018 32
Table 18: CD Therapeutics Market, Japan, Revenue ($m), 2005 - 2010 33
Table 19: CD Therapeutics Market, Japan, Forecast ($m), 2010 - 2018 34
Table 20: CD Therapeutics - Phase III Pipeline, 2011 47
Table 21: CD Therapeutics - Phase II/III Pipeline, 2011 47
Table 22: CD Therapeutics - Phase II Pipeline, 2011 48
Table 23: CD Therapeutics - Phase I/II Pipeline, 2011 48
Table 24: CD Therapeutics - Phase I Pipeline, 2011 49
Table 25: CD Therapeutics - Preclinical Pipeline, 2011 49
Table 26: CD Therapeutics - Discovery Pipeline, 2011 49
Table 27: CD Therapeutics - Mechanism of Action That Constitute Others in the Pie Chart in Figure 29 50
Table 28: Crohn’s Disease Therapeutics - Most Promising Drugs Under Clinical Development 52
Table 29: CD Therapeutics - Clinical Trials by Country, 2011 56
Table 30: CD Therapeutics - Clinical Trials by Phase, 2011 57
Table 31: CD Therapeutics - Clinical Trials by Status, 2011 58
Table 32: CD Therapeutics - Overall Sponsors, 2011 59
Table 33: CD Therapeutics - Prominent Sponsors, 2011 60
Table 34: CD Therapeutics - Top Companies Participating in Therapeutics Clinical Trials, 2011 61
Table 35: GlaxoSmithKline (GSK) Autoimmune and Gastrointestinal Disease Pipeline Products, June 2011 65
Table 36: Johnson & Johnson (J&J) Autoimmune and Gastrointestinal Disease Pipeline Products, 2011 66
Table 37: Osiris Inc, Autoimmune and Gastrointestinal Disease Pipeline Products, June 2011 67
Table 38: Takeda Pharmaceutical Company Limited Autoimmune and Gastrointestinal Disease Pipeline Products, June 2011 69
Table 39: Licensing and Partnership Deals 70

List of Figures

Figure 1: Pathophysiology of CD 12
Figure 2: ICD Treatment Algorithm 14
Figure 3: Perianal Complications Treatment Algorithm 15
Figure 4: CD Therapeutics Market, Global, Revenue ($bn), 2005 - 2010 17
Figure 5: CD Therapeutics, Market Share ($m, %), 2010 18
Figure 6: CD Therapeutics Market, Global, Forecast ($bn), 2010 - 2018 19
Figure 7: CD Therapeutics, Market Share ($m, %), 2018 20
Figure 8: CD Therapeutics Market, The US, Revenue ($bn), 2005 - 2010 21
Figure 9: CD Therapeutics Market, The US, Forecast ($bn), 2010 - 2018 22
Figure 10: CD Therapeutics Market, France, Revenue ($m), 2005 - 2010 23
Figure 11: CD Therapeutics Market, France, Forecast ($m), 2010 - 2018 24
Figure 12: CD Therapeutics Market, Germany , Revenue ($m), 2005 - 2010 25
Figure 13: CD Therapeutics Market, Germany , Forecast ($m), 2010 - 2018 26
Figure 14: CD Therapeutics Market, Italy, Revenue ($m), 2005 - 2010 27
Figure 15: CD Therapeutics Market, Italy, Forecast ($m), 2010 - 2018 28
Figure 16: CD Therapeutics Market, Spain, Revenue ($m), 2005 - 2010 29
Figure 17: CD Therapeutics Market, Spain, Forecast ($m), 2010 - 2018 30
Figure 18: CD Therapeutics Market, The UK, Revenue ($m), 2005 - 2010 31
Figure 19: CD Therapeutics Market, The UK, Forecast ($m), 2010 - 2018 32
Figure 20: CD Therapeutics Market, Japan, Revenue ($m), 2005 - 2010 33
Figure 21: CD Therapeutics Market, Japan, Forecast ($m), 2010 - 2018 34
Figure 22: CD Therapeutics, Key Events Impacting Future Market 36
Figure 23: Opportunity and Unmet Need in the CD Therapeutics Market,2010 37
Figure 24: Strategic Competitor Assessment of the Major Marketed Products in CD, 2010 39
Figure 25: CD Therapeutics Pipeline by Phase of Clinical Development, 2011 47
Figure 26: CD Therapeutics-Clinical Pipeline by Mechanism of Action 50
Figure 27: Technology Trends Analytical Framework of The CD Therapeutics Pipeline, 2011 51
Figure 28: Technology Trends Analytical Framework of The CD Therapeutics Pipeline - Description, 2011 51
Figure 29: CD Therapeutics - Clinical Trials by Country, 2011 56
Figure 30: CD Therapeutics - Clinical Trials by Phase, 2011 57
Figure 31: CD Therapeutics - Clinical Trials by Status, 2011 58
Figure 32: CD Therapeutics - Overall Sponsors, 2011 59
Figure 33: CD Therapeutics - Prominent Sponsors, 2011 60
Figure 34: CD Therapeutics - Top Companies Participating in Therapeutics Clinical Trials, 2011 61
Figure 35: Implications for Future Market Competition in the CD Therapeutics Market, 2010 62
Figure 36: CD Therapeutics Market, Clinical Pipeline by Company, June 2011 63
Figure 37: GlobalData Market Forecasting Model 77